Ocugen, Inc.
NASDAQ:OCGNBiotechnology
+$0.03 today
- Market cap
- $250.82M
- Beta
- 2.21
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.22
Volume 5.83M
Average 7.51M
OCGN Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Ocugen, Inc.NASDAQ: OCGN
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $1.53M rose 3.5% year over year, ahead of the -1.3% change in trailing-twelve-month revenue. Over 3 fiscal years it compounded at +21.0% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 5 analysts of $5.67M (+28.5%) for the fiscal year ending Dec 2026, a step up from the +8.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.53M+894.3% QoQ
- Last fiscal yearDec 2025
- $4.41M+8.8% YoY
- LTMMar 2026
- $4.47M-1.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.5% | -35.3% | -38.8 pp |
| 1 year | +8.8% | +28.5% | +19.6 pp |
| 3-year CAGR | +21.0% | +221.8% | +200.8 pp |
| 5-year CAGR | +203.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 4.41M USD
- Year-over-year change
- +8.8%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.41M | +8.8% |
| FY2024 | 2024-12-31 | 4.06M | -32.8% |
| FY2023 | 2023-12-31 | 6.04M | +142.6% |
| FY2022 | 2022-12-31 | 2.49M | — |
| FY2021 | 2021-12-31 | 0 | — |
Revenue vs competitors
How OCGN compares with its peers on the latest reported figures
- OCGN's LTM Mar 2026 revenue of $4.47M is the 6th highest of the 10 companies compared; the peer median is $7.4M.
- Its year-over-year change of -1.3% is the 4th highest of 8, against a peer median of -63.1%.
- Over three fiscal years its annual growth of +21.0% compares with a peer median of -0.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $79.18M | +4.4% | -27.1% | |
| LTM Mar 2026 | $69.64M | +123.1% | +610.3% | |
| LTM Mar 2026 | $14.78M | +54.6% | -0.3% | |
| LTM Mar 2026 | $9.89M | — | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $7.4M | -63.1% | — |
| LTM Mar 2026 | $4.47M | -1.3% | +21.0% | |
| LTM Mar 2026 | $0 | -100.0% | — | |
| LTM Mar 2026 | $0 | -100.0% | — | |
| LTM Mar 2026 | $0 | -100.0% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 | — | — |
| Peer median (excluding OCGN) | $7.4M | -63.1% | -0.3% | |
Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 2.49M | 6.04M | 4.06M | 4.41M |
| Cost of Revenue | 0 | 0 | 704K | 1.97M | 2.39M |
| Gross Profit | 0 | 2.49M | 5.33M | 2.09M | 2.02M |
| Gross Margin | — | 100.0% | 88.3% | 51.5% | 45.9% |
| Research & Development | 35.11M | 56.16M | 39.57M | 32.13M | 39.75M |
| Selling, General & Admin | 22.92M | 35.4M | 31.99M | 26.69M | 27.58M |
| Operating Expenses | 58.03M | 91.56M | 70.86M | 56.84M | 64.94M |
| Depreciation & Amortization | 229K | 480K | 704K | 1.97M | 2.39M |
| EBITDA | (58.11M) | (86.32M) | (62.37M) | (52.09M) | (60.27M) |
| EBITDA Margin | — | -3469.6% | -1033.4% | -1284.5% | -1365.7% |
| Operating Income | (58.03M) | (89.07M) | (65.53M) | (54.76M) | (62.92M) |
| Operating Margin | — | -3580.0% | -1085.7% | -1350.4% | -1425.7% |
| Interest Income | 0 | 1.4M | 2.5M | 1.3M | 922K |
| Interest Expense | 79K | 0 | 0 | 0 | 5.19M |
| Other Income / Expenses | (389K) | 2.27M | 2.45M | 703K | (4.93M) |
| Income Before Tax | (58.42M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Pre-Tax Margin | — | -3488.9% | -1045.0% | -1333.0% | -1537.4% |
| Income Tax Expense | (52K) | 0 | 0 | 0 | 0 |
| Net Income | (58.37M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Net Margin | — | -3488.9% | -1045.0% | -1333.0% | -1537.4% |
| EPS (Basic) | (0.30) | (0.40) | (0.26) | (0.20) | (0.23) |
| EPS (Diluted) | (0.30) | (0.40) | (0.26) | (0.20) | (0.23) |
| Weighted Avg Shares | 195.01M | 214.6M | 244.33M | 271M | 300.17M |
| Weighted Avg Shares (Diluted) | 195.01M | 214.6M | 244.33M | 271M | 300.17M |
Ocugen, Inc.
NASDAQ:OCGN
Intrinsic Alpha fair value
Locked
Current Price
$0.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.